Specgx Llc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SPECGX LLC, and what generic alternatives to SPECGX LLC drugs are available?
SPECGX LLC has sixty approved drugs.
There is one US patent protecting SPECGX LLC drugs.
There are ten patent family members on SPECGX LLC drugs in nine countries and thirty supplementary protection certificates in ten countries.
Summary for Specgx Llc
| International Patents: | 10 |
| US Patents: | 1 |
| Tradenames: | 47 |
| Ingredients: | 31 |
| NDAs: | 60 |
| Drug Master File Entries: | 73 |
Drugs and US Patents for Specgx Llc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Specgx Llc | METHYLPHENIDATE HYDROCHLORIDE | methylphenidate hydrochloride | TABLET;ORAL | 040300-001 | Nov 27, 1998 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Specgx Llc | FENTANYL CITRATE | fentanyl citrate | TROCHE/LOZENGE;TRANSMUCOSAL | 078907-002 | Oct 30, 2009 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Specgx Llc | DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE | amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 211546-004 | Aug 31, 2023 | AB2 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Specgx Llc | METHYLPHENIDATE HYDROCHLORIDE | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 202608-001 | Dec 28, 2012 | BX | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Specgx Llc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Specgx Llc | EXALGO | hydromorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021217-003 | Mar 1, 2010 | 5,914,131 | ⤷ Sign Up |
| Specgx Llc | EXALGO | hydromorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021217-002 | Mar 1, 2010 | 5,702,725 | ⤷ Sign Up |
| Specgx Llc | EXALGO | hydromorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021217-001 | Mar 1, 2010 | 5,914,131 | ⤷ Sign Up |
| Specgx Llc | PAMELOR | nortriptyline hydrochloride | CAPSULE;ORAL | 018013-001 | Approved Prior to Jan 1, 1982 | 3,922,305 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SPECGX LLC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Oral Solution | 5 mg/5 mL and 10 mg/5 mL | ➤ Subscribe | 2010-04-13 |
International Patents for Specgx Llc Drugs
Supplementary Protection Certificates for Specgx Llc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0736030 | 06C0009 | France | ⤷ Sign Up | PRODUCT NAME: POSACONAZOLE; REGISTRATION NO/DATE: EU/1/05/320/001 20051025 |
| 1635783 | CA 2014 00016 | Denmark | ⤷ Sign Up | PRODUCT NAME: FENTANYL I EN HVILKEN SOM HELST AF DE FORMER, DER ER BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/10/644/001-006 20100831 |
| 1769785 | C300521 | Netherlands | ⤷ Sign Up | PRODUCT NAME: FENTANYL; REG NO/DATE: EU/2/11/127/001 20111006 |
| 1635783 | C300653 | Netherlands | ⤷ Sign Up | PRODUCT NAME: FENTANYL IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VERSCHIJNINGSVORM; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100906 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
